Trulieve Cannabis Corp. (CSE:TRUL) shareholders won’t be pleased to see that the share price has had a very rough month, dropping 28% and undoing the prior period’s positive performance. Of course, over the longer-term many would still wish they owned shares as the stock’s price has soared 121% in the last twelve months.
In spite of the heavy fall in price, there still wouldn’t be many who think Trulieve Cannabis’ price-to-sales (or “P/S”) ratio of 1.4x is worth a mention when the median P/S in Canada’s Pharmaceuticals industry is similar at about 1.2x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.
View our latest analysis for Trulieve Cannabis
How Trulieve Cannabis Has Been Performing
While the industry has experienced revenue growth lately, Trulieve Cannabis’ revenue has gone into…
